Skip to the main content.

essential oils for third trimester support

Join a research study

Enrolling is simple

Our research team is enrolling for a randomized controlled trial evaluating daily use of essential oils as a supportive tool for pregnancy and birth. This study is open to healthy women who are 20 years or older with a low risk pregnancy.  

Participation is easy. After enrollment, you will be given a packet of a massage oil and some saliva collection tubes. At the start of your third trimester, you'll provide saliva samples, then start using the massage oil daily. When you are full term, you'll provide two saliva samples again and stop using the massage oil. After you give birth, we'll collect some health information about the birth. 

You'll also receive $200 as a thank you for participating. 

Ready to join this study? Submit the form below and our researchers will be in touch with more information.

One

Sign up Below

Complete the form below to enroll. One of our research team members will send you more information within 24 hours.

Two

Meet with us

Spend 10-15 minutes on-site with one of our researchers to get your materials and learn more about the study. 

Three

Use the Massage Oil

After your on-site visit, you'll be all set to finish the study from the comfort of your own home. 

Ready to get started? Want more info? Complete the form below. Within 24 hours, one of our researchers will email you with more information. 

Important Info

The purpose of this study is to measure the effects of daily topical application of aromatherapy during the third trimester. The protocol for this trial was developed by clinical aromatherapists, and the study is conducted in partnership with the National Association for Holistic Aromatherapists. The protocol has been evaluated and approved by an independent third-party ethical review board which is accredited by the US Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP). It is conducted in compliance with the Declaration of Helsinki, the Belmont Report, the regulations outlined in 45 CFR 46, and ICH GCP E6 (R2). The protocol is also registered at a World Health Organization (WHO) approved clinical trial registry.